|
業務類別
|
Biotechnology |
|
業務概覽
|
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. Thecompany provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner. |
| 公司地址
| 45 Wiggins Avenue, Bedford, MA, USA, 01730 |
| 電話號碼
| +1 781 430-8200 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.stoketherapeutics.com |
| 員工數量
| 170 |
| Mr. Ian F. Smith |
Chief Executive Officer and Director |
美元 170.63K |
22/04/2026 |
| Mr. Jason Hoitt |
Chief Patient Officer |
美元 494.40K |
22/04/2026 |
| Mr. Thomas E. Leggett |
Chief Financial Officer and Principal Accounting Officer |
美元 496.38K |
22/04/2026 |
| Mr. Barry S. Ticho, M.D.,PhD |
Chief Medical Officer |
-- |
22/04/2026 |
| Mr. Jonathan Allan |
General Counsel and Corporate Secretary |
-- |
22/04/2026 |
|
|
| Mr. Ian F. Smith |
Chief Executive Officer and Director |
22/04/2026 |
| Dr. Arthur A. Levin,PhD |
Independent Director |
22/04/2026 |
| Dr. Seth L. Harrison, M.D. |
Independent Director |
22/04/2026 |
| Dr. Edward M. Kaye, M.D. |
Director |
22/04/2026 |
| Ms. Julie Anne Smith |
Independent Director |
22/04/2026 |
| Dr. Arthur O. Tzianabos, PhD |
Chairman of the Board |
22/04/2026 |
| Ms. Jennifer C. Burstein, C.P.A. |
Independent Director |
22/04/2026 |
| Professor Adrian R. Krainer, PhD |
Independent Director |
22/04/2026 |
| Dr. G. Clare Kahn, PhD |
Independent Director |
07/04/2026 |
|
|
|
|
